Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205482 | 0.90 | CACNA1H (0.55) | CACNA1HHSD11B1TRPV1 | |
| SCHEMBL8226841 | 0.90 | TRPV1 (0.54) | CACNA1HTRPV1RORC | |
| SCHEMBL8217952 | 0.83 | HDAC1 (0.52) | CACNA1HTRPV1 | |
| SCHEMBL8212694 | 0.82 | TRPV1 (0.61) | CACNA1HTRPV1TSHRRORC | |
| SCHEMBL8227841 | 0.81 | TRPV1 (0.55) | CACNA1HTRPV1TSHR | |
| SCHEMBL8217835 | 0.81 | TRPV1 (0.55) | TRPV1TSHR | |
| SCHEMBL8209853 | 0.80 | TRPV1 (0.55) | CACNA1HTRPV1 | |
| SCHEMBL8217950 | 0.80 | CACNA1H (0.54) | CACNA1HHSD11B1TRPV1 | |
| SCHEMBL14263432 | 0.80 | CACNA1H (0.54) | CACNA1HTRPV1 | |
| SCHEMBL8217839 | 0.78 | CACNA1H (0.49) | CACNA1HTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2008033468-A2 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | CYP46A1, OPRD1, OPRK1 | CACNA1H 1386/4885HSD11B1 244/4885TRPV1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.